DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riska, P. S.
Right arrow Articles by Hattox, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riska, P. S.
Right arrow Articles by Hattox, S. E.

Vol. 27, Issue 12, 1434-1447, December 1999

Biotransformation of Nevirapine, a Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor, in Mice, Rats, Rabbits, Dogs, Monkeys, and Chimpanzees1

Paul S. Riska, David P. Joseph, Roger M. Dinallo, Walter C. Davidson, James J. Keirns, and Susan E. Hattox

Departments of Drug Metabolism and Pharmacokinetics (P.S.R., D.P.J., J.J.K., S.E.H.) and Analytical Sciences (R.M.D., W.C.D.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

The study objectives were to characterize the metabolism of nevirapine (NVP) in mouse, rat, rabbit, dog, monkey, and chimpanzee after oral administration of carbon-14-labeled or -unlabeled NVP. Liquid scintillation counting quantitated radioactivity and bile, plasma, urine, and feces were profiled by HPLC/UV diode array and radioactivity detection. Metabolite structures were confirmed by UV spectral and chromatographic retention time comparisons with synthetic metabolite standards, by beta -glucuronidase incubations, and in one case, by direct probe electron impact ionization/mass spectroscopy, chemical ionization/mass spectroscopy, and NMR. NVP was completely absorbed in both sexes of all species except male and female dogs. Parent compound accounted for <6% of total urinary radioactivity and <5.1% of total fecal radioactivity, except in dogs where 41 to 46% of the radioactivity was excreted as parent compound. The drug was extensively metabolized in both sexes of all animal species studied. Oxidation to hydroxylated metabolites occurred before glucuronide conjugation and excretion in urine and feces. Hydroxylated metabolites were 2-, 3-, 8-, and 12-hydroxynevirapine (2-, 3-, 8-, and 12-OHNVP). 4-carboxynevirapine, formed by secondary oxidation of 12-OHNVP, was a major urinary metabolite in all species except the female rat. Glucuronides of the hydroxylated metabolites were major or minor metabolites, depending on the species. Rat plasma profiles differed from urinary profiles with NVP and 12-OHNVP accounting for the majority of the total radioactivity. Dog plasma profiles, however, were similar to the urinary profiles with 12-OHNVP, its glucuronide conjugate, 4-carboxynevirapine, and 3-OHNVP glucuronide being the major metabolites. Overall, the same metabolites are formed in animals as are formed in humans.


1   This work has been previously presented in abstract form at meetings, as follows: Riska PS, Joseph DP, Dinallo RP, Hattox SE and Keirns JJ, Metabolism of Nevirapine, A NonNucleoside Reverse Transciptase Inhibitor, in Mouse, Rat, Dog, Rabbit and Monkey, and Riska PS, Lamson MJ, Sabo JP, Hattox SE, and Keirns JJ, Metabolism And Excretion of Nevirapine, A NonNucleoside Reverse Transcriptase Inhibitor, in Man, 7th North American ISSX Meeting, October 20-24, 1996, San Diego, CA.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Qian, S. A. Bai, B. Brogdon, J.-T. Wu, R.-Q. Liu, M. B. Covington, K. Vaddi, R. C. Newton, M. J. Fossler, C. E. Garner, et al.
Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor {alpha}-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans
Drug Metab. Dispos., October 1, 2007; 35(10): 1916 - 1925.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Nakamura, H. Nakasa, I. Ishii, N. Ariyoshi, T. Igarashi, S. Ohmori, and M. Kitada
Effects of Endogenous Steroids on CYP3A4-Mediated Drug Metabolism by Human Liver Microsomes
Drug Metab. Dispos., May 1, 2002; 30(5): 534 - 540.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.